SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
SpringWorks Therapeutics has raised $275.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2023.
SpringWorks Therapeutics's investors include Bain Capital, Samsara BioCapital, Perceptive Advisors, OrbiMed, Bain Capital Life Sciences.
SpringWorks Therapeutics is headquartered in Stamford, United States.
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
SpringWorks Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SpringWorks Therapeutics — Funding & Investors." VCBacked, December 4, 2023, https://www.vcbacked.co/company/springworks-therapeutics. Accessed November 13, 2026.
VCBacked. (2023). SpringWorks Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/springworks-therapeutics
{{cite web |title=SpringWorks Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/springworks-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at SpringWorks Therapeutics? Request a listing update